Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01785329
Recruitment Status : Completed
First Posted : February 7, 2013
Last Update Posted : August 19, 2013
Regeneron Pharmaceuticals
Information provided by (Responsible Party):